Related Experiment Video
Updated: Jun 25, 2025
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Innovative Drug Modalities for the Treatment of Advanced Prostate Cancer
Maurizio Capuozzo1, Mariachiara Santorsola2, Monica Ianniello3
1Coordinamento Farmaceutico, ASL-Naples-3, 80056 Ercolano, Italy.
Abstract:
Prostate cancer, a prevalent malignancy affecting the prostate gland, is a significant global health concern. Androgen-deprivation therapy (ADT) has proven effective in controlling advanced disease, with over 50% of patients surviving at the 10-year mark. However, a diverse spectrum of responses exists, and resistance to ADT may emerge over time. This underscores the need to explore innovative treatment strategies for effectively managing prostate cancer progression. Ongoing research endeavors persist in unraveling the complexity of prostate cancer and fostering the development of biologic and innovative approaches, including immunotherapies and targeted therapies. This review aims to provide a valuable synthesis of the dynamic landscape of emerging drug modalities in this context. Interestingly, the complexities posed by prostate cancer not only present a formidable challenge but also serve as a model and an opportunity for translational research and innovative therapies in the field of oncology.
Insights
Prostate cancer treatments like androgen-deprivation therapy (ADT) show promise, but resistance necessitates new strategies. Research focuses on innovative therapies, including immunotherapies and targeted drugs, to improve patient outcomes.
Area of Science:
- Oncology
- Urologic Oncology
- Cancer Therapeutics
Background:
- Prostate cancer is a major global health concern.
- Androgen-deprivation therapy (ADT) is a standard treatment for advanced prostate cancer, improving long-term survival for many.
- Treatment resistance to ADT can develop, highlighting the need for novel therapeutic approaches.
Purpose of the Study:
- To review emerging drug modalities for prostate cancer management.
- To synthesize current research on innovative treatments beyond ADT.
- To explore the potential of immunotherapies and targeted therapies in prostate cancer.
Main Methods:
- This is a review article, synthesizing existing literature.
- The focus is on recent advancements in prostate cancer drug development.
- Key areas include biologic therapies, immunotherapies, and targeted agents.
Main Results:
- ADT is effective but not universally curative due to resistance.
- Emerging therapies like immunotherapies and targeted drugs show potential.
- Prostate cancer research serves as a model for translational oncology.
Conclusions:
- Innovative treatment strategies are crucial for overcoming ADT resistance in prostate cancer.
- The development of novel drug modalities offers new hope for patients.
- Prostate cancer research drives advancements in oncology therapeutics.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...